Stockpolly
Search
LXRX · NASDAQ · Biotechnology

Lexicon Pharmaceuticals (LXRX)

Develops medicines for heart failure, cardiometabolic conditions, and neuropathic pain.

$2.25
Pre-market0.00 (0.00%)
At close$2.25(+2.74%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0112227129145211
Cost of revenue01500026000000
Gross profit0−141121129145211
503346576533272526202227
Research & development181514182627151619111317
320323940012989910
Selling & marketing3000000000000
General & administrative3032000000000
Other expenses0180007000000
Operating income−50−47−45−55−64−33−264−12−15−1−27
−1−3−32−1−100−1−10−5
Interest income322433222122
Interest expense455254222223
Other non-operating income−3−1−1−4−3−12−2−2−2−1−23
Income before tax−51−50−48−53−65−34−253−13−16−1−32
Net income from continuing operations−51−50−48−53−65−34−253−13−16−1−32
Net income−51−50−48−53−65−34−253−13−16−1−32
EPS, basic−$0.21−$0.20−$0.20−$0.17−$0.18−$0.09−$0.07$0.01−$0.04−$0.04−$0.00−$0.07
EPS, diluted−$0.21−$0.20−$0.20−$0.17−$0.18−$0.09−$0.07$0.01−$0.04−$0.04−$0.00−$0.07
Weighted average shares, basic245245245311361361362363363363400438
Weighted average shares, diluted245245245311361361362364363363400438
EBITDA−46−45−44−51−60−20−236−10−131−29
Depreciation & amortization000000000000
EBIT−47−45−45−51−60−20−236−11−131−29